In chronic lymphocytic leukemia, increased levels of CD52+ LMVs (CD52 is the most prevalent marker of peripheral lymphocytes) have been proposed as useful biomarkers for monitoring disease progression [57], and LMVs derived from B-cells for the prediction of treatment time and overall survival [137]. Here, CD52 is linked to B-cell chronic lymphocytic leukemia.